Last reviewed · How we verify
Placebo (for Pitavastatin)
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
At a glance
| Generic name | Placebo (for Pitavastatin) |
|---|---|
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is not a drug with a mechanism of action. It is used in randomized controlled trials as a comparator to assess the efficacy and safety of the active drug (in this case, Pitavastatin, a statin). Any observed effects in the placebo group are attributed to the placebo effect or natural disease progression.
Approved indications
Common side effects
Key clinical trials
- Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides (PHASE4)
- Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (PHASE3)
- Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (PHASE3)
- PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) (PHASE3)
- Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia (PHASE3)
- Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia (PHASE3)
- Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer (PHASE2, PHASE3)
- Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Pitavastatin) CI brief — competitive landscape report
- Placebo (for Pitavastatin) updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI